189.68
Schlusskurs vom Vortag:
$190.65
Offen:
$189.92
24-Stunden-Volumen:
1.50M
Relative Volume:
1.33
Marktkapitalisierung:
$10.70B
Einnahmen:
$763.34M
Nettoeinkommen (Verlust:
$51.40M
KGV:
208.81
EPS:
0.9084
Netto-Cashflow:
$104.46M
1W Leistung:
+7.23%
1M Leistung:
+4.40%
6M Leistung:
+65.92%
1J Leistung:
+55.88%
Repligen Corp Stock (RGEN) Company Profile
Firmenname
Repligen Corp
Sektor
Telefon
(781) 449-9560
Adresse
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, RMD, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
RGEN
Repligen Corp
|
189.68 | 10.70B | 763.34M | 51.40M | 104.46M | 0.9084 |
|
ISRG
Intuitive Surgical Inc
|
405.18 | 143.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
183.82 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
RMD
Resmed Inc
|
222.00 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
|
ALC
Alcon Inc
|
64.47 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
34.70 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-09 | Fortgesetzt | UBS | Buy |
| 2026-07-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2026-06-02 | Fortgesetzt | Wolfe Research | Outperform |
| 2026-05-15 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2026-04-17 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-01 | Eingeleitet | HSBC Securities | Buy |
| 2025-09-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-29 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | Evercore ISI | In-line |
| 2025-02-10 | Eingeleitet | TD Cowen | Buy |
| 2024-12-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-07-20 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-03-28 | Eingeleitet | The Benchmark Company | Buy |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2021-10-14 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-11-01 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | Eingeleitet | SVB Leerink | Outperform |
| 2019-08-28 | Bestätigt | First Analysis Sec | Outperform |
| 2019-08-23 | Fortgesetzt | Stephens | Overweight |
| 2019-07-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | Hochstufung | CL King | Neutral → Buy |
| 2018-11-12 | Herabstufung | CL King | Buy → Neutral |
| 2018-09-26 | Eingeleitet | H.C. Wainwright | Neutral |
| 2017-12-08 | Eingeleitet | Citigroup | Buy |
| 2017-12-05 | Eingeleitet | JP Morgan | Overweight |
| 2017-11-13 | Eingeleitet | CL King | Buy |
| 2017-10-02 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | Eingeleitet | William Blair | Outperform |
| 2017-02-13 | Hochstufung | Piper Jaffray | Neutral → Overweight |
Alle ansehen
Repligen Corp Aktie (RGEN) Neueste Nachrichten
Form 4 Repligen Corporation For: 26 September By Investing.com - Investing.com India
Repligen CEO Loeillot sells $2.46m in shares - Investing.com
Repligen CEO Loeillot sells $2.46m in shares By Investing.com - Investing.com Australia
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 12,946 Shares - GuruFocus
Repligen (RGEN) CEO sells shares at $190 each after exercising options under a trading plan. - Stock Titan
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Form 144 REPLIGEN CORP For: 24 September By Investing.com - Investing.com Nigeria
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
Is Repligen Corp (RGEN) Overvalued After 3.3% Rally? GF Value Sa - GuruFocus
Shares valued at $2.46 million are listed for sale by a Repligen (NASDAQ: RGEN) officer and director. - Stock Titan
Repligen Corp Stock Baskets - GuruFocus
Repligen Corp (BSP:R2GE34) Stock Price & 30 Year Financial Data - GuruFocus
Repligen Corporation stock hits 52-week high at 188.95 USD - Investing.com
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen Corp (RGEN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 87/100 - GuruFocus
Repligen (RGEN) CEO sells 5,426 shares under plan - Stock Titan
Biolife Solutions stock hits 52-week high at $38.10 By Investing.com - Investing.com Canada
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
Repligen (NASDAQ: RGEN) insider plans new stock sale after two recent trades - Stock Titan
Repligen Stock Price Forecast. Should You Buy RGEN? - StockInvest.us
Repligen (NASDAQ: RGEN) Director Karen Dawes to Step Down on September 30, 2026 - Kalkine Media
Karen A. Dawes to Retire from Repligen Board Effective Sept 30, 2026 - TradingView
Could Pricing Pressure Change the Repligen (NASDAQ:RGEN) Story? - Kalkine Media
BioLife Solutions merger with Repligen advances as antitrust waiting period ends - Investing.com
BioLife Solutions' HSR Antitrust Waiting Period Ends Ahead of Repligen Merger - Kalkine Media
Repligen at Wells Fargo conference: growth broadens beyond headwinds - Investing.com
REPLIGEN CEO Loeillot Olivier Forfeits 2,842 Shares at $169.61 and Sells 3,035 Shares at $165.90 (NASDAQ: RGEN) - Kalkine Media
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead - Yahoo Finance
Repligen to acquire BioLife for $11.25 cash plus 0.1442 shares per BioLife share; HSR waiting period expired - TradingView
[425] REPLIGEN CORP Business Combination Communication | RGEN SEC FilingForm 425 - Stock Titan
Repligen (RGEN) CEO trades stock in preset plan - Stock Titan
Repligen (NASDAQ: RGEN) Schedules October 5 Vote for BioLife Merger Approval - Kalkine Media
REPLIGEN CORP SEC Filing (Sep 8, 2026) - Stock Titan
ZimVie Inc. When-Issued (ZIMVV) Peer Comparison – Compare with Others - Value Research
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup - ChartMill
Repligen Corporation (RGEN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Repligen (RGEN) holder lines up new sale after $976K trade - Stock Titan
Heska Corporation (HSKA) Peer Comparison – Compare with Others - Value Research
What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share - Stock Titan
Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound - Yahoo Finance
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Codex DNA Inc (DNAY) Peer Comparison – Compare with Others - Value Research
Repligen (NASDAQ: RGEN) awards 2,466 stock units to its chief accounting officer - Stock Titan
A Look at Repligen Corp (RGEN) After 6.1% Decline -- GF Value $1 - GuruFocus
Apria Inc. (APR) Peer Comparison – Compare with Others - Value Research
Repligen Shares Slide as Market Weighs BioLife Deal Dilution and Execution Risk - Quiver Quantitative
Acutus Medical Inc (AFIB) Peer Comparison – Compare with Others - Value Research
Repligen Corporation (RGEN) Stock Price, Chart, News & Analysis - securities.io
Repligen Corporation (RGEN) Peer Comparison – Compare with Others - Value Research
Repligen Corp (RGEN) Shares Fall 3.2% -- What GF Score of 87 Tel - GuruFocus
Finanzdaten der Repligen Corp-Aktie (RGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Repligen Corp-Aktie (RGEN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer |
Sep 24 '26 |
Sale |
190.00 |
12,946 |
2,459,740 |
48,369 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):